DNB Asset Management AS Increases Position in Tempus AI, Inc. $TEM

DNB Asset Management AS lifted its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 27.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,183 shares of the company’s stock after buying an additional 7,925 shares during the quarter. DNB Asset Management AS’s holdings in Tempus AI were worth $2,363,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Tempus AI by 6,247.5% in the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock worth $289,204,000 after purchasing an additional 5,900,668 shares during the period. Geode Capital Management LLC increased its stake in Tempus AI by 411.4% in the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock worth $41,264,000 after buying an additional 522,443 shares during the period. KADENSA CAPITAL Ltd purchased a new position in Tempus AI in the 1st quarter worth about $22,130,000. Jump Financial LLC bought a new stake in Tempus AI during the 1st quarter valued at about $8,545,000. Finally, Aberdeen Group plc boosted its position in Tempus AI by 209.0% in the 1st quarter. Aberdeen Group plc now owns 254,730 shares of the company’s stock valued at $12,288,000 after buying an additional 172,280 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $76.84 on Wednesday. The firm has a 50 day moving average of $83.25 and a 200 day moving average of $72.40. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $13.67 billion, a price-to-earnings ratio of -64.57 and a beta of 4.86. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business’s revenue was up 84.7% compared to the same quarter last year. During the same period last year, the business posted ($0.46) EPS. Tempus AI has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Ryan Fukushima sold 10,099 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total value of $661,888.46. Following the sale, the chief operating officer directly owned 829,081 shares in the company, valued at approximately $54,337,968.74. This trade represents a 1.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James William Rogers sold 7,257 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total transaction of $475,623.78. Following the transaction, the chief financial officer owned 131,216 shares of the company’s stock, valued at approximately $8,599,896.64. This trade represents a 5.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,071,888 shares of company stock worth $84,144,336 over the last ninety days. 26.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

TEM has been the topic of a number of research reports. HC Wainwright reduced their target price on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. TD Cowen downgraded Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price objective on the stock. in a report on Tuesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Guggenheim increased their price target on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, September 26th. Finally, BTIG Research lifted their price objective on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tempus AI has a consensus rating of “Hold” and a consensus target price of $80.75.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.